{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T23:34:12Z","timestamp":1648856052390},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"DOI":"10.2146\/ajhp130752","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T09:53:25Z","timestamp":1408614805000},"page":"1443-1448","source":"Crossref","is-referenced-by-count":1,"title":["Pomalidomide for the management of refractory multiple myeloma"],"prefix":"10.1093","volume":"71","author":[{"given":"Bryant B.","family":"Summers","sequence":"first","affiliation":[{"name":"Bryant B. Summers, Pharm.D., is Drug Information Resident; Sabrina W. Cole, Pharm.D., BCPS, is Assistant Professor of Pharmacy; and Jacqueline L. Olin, M.S., Pharm.D., BCPS, CPP, CDE, FASHP, is Associate Professor of Pharmacy, Wingate University School of Pharmacy, Wingate, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina W.","family":"Cole","sequence":"additional","affiliation":[{"name":"Bryant B. Summers, Pharm.D., is Drug Information Resident; Sabrina W. Cole, Pharm.D., BCPS, is Assistant Professor of Pharmacy; and Jacqueline L. Olin, M.S., Pharm.D., BCPS, CPP, CDE, FASHP, is Associate Professor of Pharmacy, Wingate University School of Pharmacy, Wingate, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline L.","family":"Olin","sequence":"additional","affiliation":[{"name":"Bryant B. Summers, Pharm.D., is Drug Information Resident; Sabrina W. Cole, Pharm.D., BCPS, is Assistant Professor of Pharmacy; and Jacqueline L. Olin, M.S., Pharm.D., BCPS, CPP, CDE, FASHP, is Associate Professor of Pharmacy, Wingate University School of Pharmacy, Wingate, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019031208591151800_b1-0711443","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"key\n\t\t\t\t2019031208591151800_b2-0711443","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma v.2.2014. www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#myeloma (accessed 2013 Nov 24)."},{"key":"key\n\t\t\t\t2019031208591151800_b3-0711443","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019031208591151800_b4-0711443","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019031208591151800_b5-0711443","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2013-05-484782","article-title":"Pomalidomide","volume":"122","author":"Lacy","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019031208591151800_b6-0711443","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","article-title":"Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1","volume":"107","author":"Anderson","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019031208591151800_b7-0711443","volume-title":"Pomalyst (pomalidomide) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019031208591151800_b8-0711443","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2012.07.004","article-title":"The application and biology of immunomodulatory drugs (IMiDs) in cancer","volume":"136","author":"Pan","year":"2012","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t2019031208591151800_b9-0711443","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2012-08-450742","article-title":"Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib","volume":"121","author":"Richardson","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019031208591151800_b10-0711443","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-012-2040-6","article-title":"Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration","volume":"71","author":"Hoffman","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t2019031208591151800_b11-0711443","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","article-title":"Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma","volume":"22","author":"Schey","year":"2004","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019031208591151800_b12-0711443","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07013.x","article-title":"Alternate day pomalidomide retains antimyeloma effect with reduced adverse events and evidence of in vivo immunomodulation","volume":"141","author":"Streetly","year":"2008","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2019031208591151800_b13-0711443","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019031208591151800_b14-0711443","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019031208591151800_b15-0711443","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019031208591151800_b16-0711443","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My\u00e9lome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019031208591151800_b17-0711443","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019031208591151800_b18-0711443","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019031208591151800_b19-0711443","article-title":"Thalidomide [monograph]","volume-title":"Briggs\u2019 drugs in pregnancy and lactation [mobile application]"},{"key":"key\n\t\t\t\t2019031208591151800_b20-0711443","unstructured":"Food and Drug Administration. Pomalyst (pomalidomide) risk evaluation and mitigation strategy (REMS). www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM339450.pdf (accessed 2013 Nov 24)."},{"key":"key\n\t\t\t\t2019031208591151800_b21-0711443","article-title":"Pomalidomide","volume-title":"Red book online [online database]"},{"key":"key\n\t\t\t\t2019031208591151800_b22-0711443","unstructured":"ClinicalTrials.gov. Safety and efficacy of pomalidomide, bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma (OPTIMISMM). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01734928?term=pomalidomide&rank=11 (accessed accessed 2014 Jun 19)."},{"key":"key\n\t\t\t\t2019031208591151800_b23-0711443","unstructured":"ClinicalTrials.gov. A phase 1\/2 study of pomalidomide, dexamethasone, and pegylated liposomal doxorubicin for patients with relapsed\/refractory multiple myeloma. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01541332?term=pomalidomide&rank=12 (accessed accessed 2014 Jun 19)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/17\/1443\/28048797\/ajhp1443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T09:54:21Z","timestamp":1552384461000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/17\/1443\/5110919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":23,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130752","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,9,1]]},"published":{"date-parts":[[2014,9,1]]}}}